Peter M. Irving

19.3k total citations · 4 hit papers
337 papers, 9.1k citations indexed

About

Peter M. Irving is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Peter M. Irving has authored 337 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 209 papers in Genetics, 130 papers in Epidemiology and 110 papers in Surgery. Recurrent topics in Peter M. Irving's work include Inflammatory Bowel Disease (193 papers), Microscopic Colitis (115 papers) and Gastrointestinal motility and disorders (42 papers). Peter M. Irving is often cited by papers focused on Inflammatory Bowel Disease (193 papers), Microscopic Colitis (115 papers) and Gastrointestinal motility and disorders (42 papers). Peter M. Irving collaborates with scholars based in United Kingdom, United States and Canada. Peter M. Irving's co-authors include Miranda Lomer, Kevin Whelan, Heidi M. Staudacher, Jacqueline S. Barrett, Jane G. Muir, Peter R. Gibson, Peter G. Gibson, Richard B. Gearry, Susan Shepherd and Jeremy Sanderson and has published in prestigious journals such as Science, Cell and SHILAP Revista de lepidopterología.

In The Last Decade

Peter M. Irving

314 papers receiving 8.9k citations

Hit Papers

Gluten Causes Gastrointestinal Symptoms in Subjects Witho... 2011 2026 2016 2021 2011 2012 2019 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gluten Causes Gastrointestinal Symptoms in Subjects Without Celiac Disease: A Double-Blind Randomized Placebo-Controlled Trial
    2011 516 citations Peter M. Irving et al. profile →
  2. Fermentable Carbohydrate Restriction Reduces Luminal Bifidobacteria and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome
    2012 435 citations Peter M. Irving et al. profile →
  3. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial
    2019 252 citations James O. Lindsay, Peter M. Irving et al. profile →
  4. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
    2019 228 citations Peter M. Irving, Corey A. Siegel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter M. Irving United Kingdom 52 3.8k 3.5k 2.4k 2.2k 1.7k 337 9.1k
Richard B. Gearry New Zealand 52 4.5k 1.2× 1.5k 0.4× 3.2k 1.4× 2.5k 1.1× 801 0.5× 311 9.5k
Salvatore Cucchiara Italy 58 4.3k 1.1× 4.3k 1.2× 3.3k 1.4× 5.3k 2.4× 761 0.4× 379 13.1k
E. Jan Irvine Canada 43 4.9k 1.3× 3.7k 1.1× 4.2k 1.8× 4.0k 1.8× 927 0.5× 97 10.8k
Vito Annese Italy 53 4.1k 1.1× 3.3k 0.9× 2.9k 1.2× 5.0k 2.3× 548 0.3× 254 9.9k
Rinse K. Weersma Netherlands 47 2.6k 0.7× 1.3k 0.4× 2.1k 0.9× 2.4k 1.1× 1.5k 0.9× 204 10.4k
Martin Hiele Belgium 41 4.3k 1.1× 1.9k 0.5× 3.6k 1.5× 3.8k 1.8× 1.0k 0.6× 140 9.5k
Antonio Di Sabatino Italy 58 3.3k 0.9× 2.9k 0.8× 3.2k 1.4× 3.8k 1.7× 780 0.5× 320 11.8k
David G. Binion United States 59 4.9k 1.3× 1.5k 0.4× 5.7k 2.4× 3.5k 1.6× 669 0.4× 327 12.2k
Hamed Khalili United States 47 4.2k 1.1× 1.1k 0.3× 4.0k 1.7× 2.1k 1.0× 676 0.4× 220 8.2k
Alessandro Ventura Italy 46 2.3k 0.6× 6.0k 1.7× 4.9k 2.0× 4.6k 2.1× 514 0.3× 415 11.7k

Countries citing papers authored by Peter M. Irving

Since Specialization
Citations

This map shows the geographic impact of Peter M. Irving's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter M. Irving with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter M. Irving more than expected).

Fields of papers citing papers by Peter M. Irving

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter M. Irving. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter M. Irving. The network helps show where Peter M. Irving may publish in the future.

Co-authorship network of co-authors of Peter M. Irving

This figure shows the co-authorship network connecting the top 25 collaborators of Peter M. Irving. A scholar is included among the top collaborators of Peter M. Irving based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter M. Irving. Peter M. Irving is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
D’Haens, Geert, Marc Ferrante, Katsuyoshi Matsuoka, et al.. (2024). P98 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the true north open-label extension study. Poster presentations. A109–A110.
3.
Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2024). Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases. 31(7). 1876–1890. 14 indexed citations
4.
Irving, Peter M., et al.. (2024). Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. Journal of Managed Care & Specialty Pharmacy. 30(9). 1026–1040. 1 indexed citations
5.
Sands, Bruce E., Geert D’Haens, David B. Clemow, et al.. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory Bowel Diseases. 30(12). 2245–2258. 26 indexed citations
6.
Schreiber, Stefan, Geert D’Haens, Fraser Cummings, et al.. (2024). Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial. Digestive and Liver Disease. 56(7). 1204–1212. 2 indexed citations
7.
Vermeire, Séverine, Andrés Yarur, David T. Rubin, et al.. (2023). P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme. Journal of Crohn s and Colitis. 17(Supplement_1). i604–i606. 3 indexed citations
8.
Ferrante, Marc, Peter M. Irving, María T. Abreu, et al.. (2023). Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial. Journal of Crohn s and Colitis. 18(3). 416–423. 5 indexed citations
9.
Dawson, Patrick, Esha Sharma, Robin Dart, et al.. (2022). P19 Risankizumab in crohn’s disease: real world experience from a pre-approval access program. Poster presentations. A45.2–A46. 2 indexed citations
10.
Honap, Sailish, Esha Sharma, Joel Mawdsley, et al.. (2022). P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study. Journal of Crohn s and Colitis. 16(Supplement_1). i414–i415. 2 indexed citations
11.
Torrente, Franco, Susanna Meade, Eric I. Benchimol, et al.. (2022). Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel. Journal of Crohn s and Colitis. 16(10). 1609–1616. 7 indexed citations
12.
Palomares, Óscar, Dirk Elewaut, Peter M. Irving, Xavier Jaumont, & Paolo Tassinari. (2022). Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?. Allergy. 77(11). 3293–3308. 30 indexed citations
13.
14.
Meade, Susanna, et al.. (2021). Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics. SHILAP Revista de lepidopterología. 2 indexed citations
15.
Goldberg, Rimma, Jennifer Clough, Luke B. Roberts, et al.. (2021). A Crohn’s Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. Journal of Crohn s and Colitis. 15(12). 2054–2065. 5 indexed citations
16.
Clough, Jennifer, et al.. (2020). Regulatory T-cell therapy in Crohn’s disease: challenges and advances. Gut. 69(5). 942–952. 124 indexed citations
17.
Kim, HoUng, Rieke Alten, Luisa Avedano, et al.. (2020). The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. 80(2). 99–113. 73 indexed citations
18.
Lindsay, James O., et al.. (2017). ECCO IBD Curriculum. Journal of Crohn s and Colitis. 11(9). 1039–1043. 4 indexed citations
19.
Campbell, S., et al.. (2014). PWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn’s Disease. Gut. 63(Suppl 1). A154.2–A155. 1 indexed citations
20.
Gibbons, Deena L., Tim Raine, Lucie Abeler‐Dörner, et al.. (2010). RGS1 is a key regulator of human T cell migration and a potential target for therapy in Inflammatory Bowel Disease (IBD). Immunology. 131. 75–75. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard B. Gearry Breakdown of academic impact, for papers by Salvatore Cucchiara Breakdown of academic impact, for papers by E. Jan Irvine Breakdown of academic impact, for papers by Vito Annese Breakdown of academic impact, for papers by Rinse K. Weersma Breakdown of academic impact, for papers by Martin Hiele Breakdown of academic impact, for papers by Antonio Di Sabatino Breakdown of academic impact, for papers by David G. Binion Breakdown of academic impact, for papers by Hamed Khalili Breakdown of academic impact, for papers by Alessandro Ventura
Rankless by CCL
2026